SG11202011849VA - Compositions and methods for treating immune thrombocytopenia - Google Patents

Compositions and methods for treating immune thrombocytopenia

Info

Publication number
SG11202011849VA
SG11202011849VA SG11202011849VA SG11202011849VA SG11202011849VA SG 11202011849V A SG11202011849V A SG 11202011849VA SG 11202011849V A SG11202011849V A SG 11202011849VA SG 11202011849V A SG11202011849V A SG 11202011849VA SG 11202011849V A SG11202011849V A SG 11202011849VA
Authority
SG
Singapore
Prior art keywords
compositions
methods
treating immune
immune thrombocytopenia
thrombocytopenia
Prior art date
Application number
SG11202011849VA
Inventor
Haard Hans De
Peter Ulrichts
Thierry Cousin
Nicolas Leupin
Torsten Dreier
Bragt Tonke Van
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of SG11202011849VA publication Critical patent/SG11202011849VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
SG11202011849VA 2018-06-08 2019-06-07 Compositions and methods for treating immune thrombocytopenia SG11202011849VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862682805P 2018-06-08 2018-06-08
US201862731947P 2018-09-16 2018-09-16
US201862732414P 2018-09-17 2018-09-17
PCT/IB2019/054786 WO2019234713A2 (en) 2018-06-08 2019-06-07 Compositions and methods for treating immune thrombocytopenia

Publications (1)

Publication Number Publication Date
SG11202011849VA true SG11202011849VA (en) 2020-12-30

Family

ID=67766190

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011849VA SG11202011849VA (en) 2018-06-08 2019-06-07 Compositions and methods for treating immune thrombocytopenia

Country Status (14)

Country Link
US (1) US20200024344A1 (en)
EP (1) EP3802590A2 (en)
JP (1) JP2021527063A (en)
KR (1) KR20210018928A (en)
CN (1) CN112513073A (en)
AU (2) AU2019283673B2 (en)
BR (1) BR112020025001A2 (en)
CA (1) CA3101462A1 (en)
IL (1) IL279265A (en)
MA (1) MA52790A (en)
MX (1) MX2020013195A (en)
PH (1) PH12020552101A1 (en)
SG (1) SG11202011849VA (en)
WO (1) WO2019234713A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021026834B1 (en) * 2008-04-25 2022-11-08 Takeda Pharmaceutical Company Limited ISOLATED ANTIBODIES BINDING FCRN, PHARMACEUTICAL COMPOSITION COMPRISING THEMSELVES AND METHODS TO DETECT AND MODULATE FCRN
MX343659B (en) 2011-06-02 2016-11-16 Dyax Corp Fc RECEPTOR BINDING PROTEINS.
BR112016014810B1 (en) 2013-12-24 2023-12-26 Argenx Bvba FCRN ANTAGONISTS AND METHODS OF USE
SG11202112010RA (en) * 2019-06-07 2021-12-30 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
CN111613323A (en) * 2020-05-15 2020-09-01 首都医科大学附属北京儿童医院 Detection method for children immune thrombocytopenia
RU2769863C1 (en) * 2020-10-08 2022-04-07 Нестерук Владимир Викторович Solid dosage form of avatrombopag and method for production thereof
CN115364106A (en) * 2021-05-17 2022-11-22 北京大学人民医院 Application of all-trans retinoic acid in combination with high-dose dexamethasone in ITP

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070107079A (en) * 2005-01-28 2007-11-06 와이어쓰 Stabilized liquid polypeptide formulations
EP1896503B1 (en) 2005-05-31 2014-10-29 Board of Regents, The University of Texas System IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF
BR122021026834B1 (en) 2008-04-25 2022-11-08 Takeda Pharmaceutical Company Limited ISOLATED ANTIBODIES BINDING FCRN, PHARMACEUTICAL COMPOSITION COMPRISING THEMSELVES AND METHODS TO DETECT AND MODULATE FCRN
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
JP6608288B2 (en) 2013-03-15 2019-11-20 アフィボディ・アーベー New polypeptide
KR101815265B1 (en) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn specific human antibody and composition for treatment of autoimmune diseases
BR112016014810B1 (en) * 2013-12-24 2023-12-26 Argenx Bvba FCRN ANTAGONISTS AND METHODS OF USE
US9763674B2 (en) 2013-12-26 2017-09-19 Ethicon Llc Ultrasonic bone cutting instrument
BR112017004189A2 (en) * 2014-09-17 2017-12-12 Affibody Ab fcn-binding dimer, fusion protein or conjugate, and, composition
US10676526B2 (en) 2015-01-30 2020-06-09 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
ES2956662T3 (en) 2015-05-12 2023-12-26 Syntimmune Inc Humanized affinity-matured anti-FcRn antibodies
CN106957365B (en) 2016-01-11 2021-03-16 上海交通大学 Monoclonal antibody FnAb8 and application thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease

Also Published As

Publication number Publication date
AU2019283673A1 (en) 2020-12-24
AU2024201185A1 (en) 2024-03-14
CA3101462A1 (en) 2019-12-12
BR112020025001A2 (en) 2021-03-23
AU2019283673B2 (en) 2023-12-07
MA52790A (en) 2021-04-14
IL279265A (en) 2021-01-31
PH12020552101A1 (en) 2021-08-02
EP3802590A2 (en) 2021-04-14
CN112513073A (en) 2021-03-16
WO2019234713A2 (en) 2019-12-12
JP2021527063A (en) 2021-10-11
MX2020013195A (en) 2021-02-26
KR20210018928A (en) 2021-02-18
WO2019234713A3 (en) 2020-02-13
US20200024344A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
IL279265A (en) Compositions and methods for treating immune thrombocytopenia
IL280134A (en) Anti-cd112r compositions and methods
IL269150A (en) Compositions and methods for treating cancer
IL275626A (en) Surface treatment compositions and methods
IL269157A (en) Compositions and methods for treating cancer
IL285886A (en) Compositions and methods for treating laminopathies
IL266562A (en) Methods and compositions for adaptive immune modulation
ZA202101362B (en) Compositions and methods for treating the eye
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
SG11202104448WA (en) Compositions and methods
SG11202011078VA (en) Compositions and methods concerning immune tolerance
ZA202101342B (en) Compositions and methods for treating the eye
IL283299A (en) Compositions and methods for immune tolerance
SG11202012435UA (en) Compositions and methods for treating cancer
IL277899A (en) Methods and compositions for treating yellow fever
GB201815262D0 (en) Composition and method
SG11202102442WA (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
GB201817444D0 (en) Methods and compositions
ZA202101361B (en) Compositions and methods for treating the eye
ZA202101360B (en) Compositions and methods for treating the eye
IL280348A (en) Surface treatment compositions and methods
IL277463A (en) Compositions and methods for treating pruritus
IL272782A (en) Compositions and methods for treating cancer
IL285796A (en) Methods and compositions for treating